FLT3 and acute myeloid leukemia: Midostaurin has demonstrated clinical activity as a single agent or in combination with chemotherapy in patients with AML [10, 11] and is currently under investigation in a phase III clinical trial in patients with newly diagnosed AML who have a mutation in FLT3 [12].